Printed From BioPortfolio.com
[Comment] Immune checkpoint inhibitors: the next step for thymic carcinomas
18:49 EST 25 Jan 2018 | The Lancet
Thymic carcinoma is a rare cancer with few available treatment options. Over the past few years, chemotherapy for thymic malignancies, comprising thymic carcinomas and thymomas, has achieved minimal success. Therefore, a more promising, targeted approach is required.1
Original Article: [Comment] Immune checkpoint inhibitors: the next step for thymic carcinomas
